Also, the combined treatment of nimotuzumab, a monoclonal antibody against epidermal growth factor receptor (EGFR), and rapamycin, an mTOR inhibitor, achieved more efficient outcomes than TMZ treatment on patient-derived human glioma cells51. This evidence concerns the gene EGFR and glioma.